Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation

BMC Pulmonary Medicine

Lilla Tamási³  Henry Chrystyn¹  Gabriele Nicolini²  Andrea Bizzi²  György Losonczy³  Noemi Eszes³  Gabriella Gálffy³  Veronika Müller³ 

[1] Division of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield, West Yorkshire, HD1 3DH, UK;Chiesi Farmaceutici S.p.A., Parma, Italy;Department of Pulmonology, Semmelweis Medical University, Budapest, Hungary

关键词: extrafine;    asthma control;    fixed combinations;    inhaler;   

Others  :  1172527
DOI  :  10.1186/1471-2466-11-40

 received in 2011-01-13, accepted in 2011-07-15,  发布年份 2011

【 摘 要 】

Background

Although patients have more problems using metered dose inhalers, clinical comparisons suggest they provide similar control to dry powder inhalers. Using real-life situations this study was designed to evaluate asthma control in outpatients with moderate to severe persistent asthma and to compare efficacy of fixed combinations of inhaled corticosteroids (ICS) and long acting beta-agonists (LABA).

Methods

This real-life study had a cross-sectional design. Patients using fixed combinations of ICS and LABA had their asthma control and spirometry assessed during regular visits.

Results

111 patients were analyzed: 53 (47.7%) received maintenance therapy of extrafine beclomethasone-formoterol (BDP/F) pressurized metered dose inhaler (pMDI), 25 (22.5%) fluticasone-salmeterol (FP/S) dry powder inhaler (DPI), and 33 (29.7%) budesonide-formoterol (BUD/F) DPI. Severity of asthma at time of diagnosis, assessed by the treating physician, was comparable among groups. Asthma control was achieved by 45.9% of patients; 38.7% were partially controlled and 15.3% were uncontrolled. In the extrafine BDF/F group, asthma control total score, daytime symptom score and rescue medication use score were significantly better than those using fixed DPI combinations (5.8 ± 6.2 vs. 8.5 ± 6.8; 1.4 ± 1.8 vs. 2.3 ± 2.1; 1.8 ± 2.2 vs. 2.6 ± 2.2; p = 0.0160; p = 0.012 and p = 0.025, respectively) and the mean daily ICS dose were significantly lower.

Conclusions

pMDI extrafine BDP/F combination demonstrated better asthma control compared to DPIs formulated with larger particles. This could be due to the improved lung deposition of the dose or less reliance on the optimal inhalation technique or both.

【 授权许可】

   
2011 Müller et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, Accordini S, Almar E, Bugiani M, Carolei A, Cerveri I, Duran-Tauleria E, Gislason D, Gulsvik A, Jõgi R, Marinoni A, Martínez-Moratalla J, Vermeire P, de Marco R: Therapy and Health Economics Group of the European Community Respiratory Health Survey. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007, 120(6):1360-7.
• [2]GINA (Global Initiative on Asthma), National Institute of Health, National Heart Lung and Blood Institute: [http://www.ginasthma.com] webciteGlobal Strategy for asthma management and prevention. 2009.
• [3]Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, GOAL Investigators Group: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170(8):836-44.
• [4]Holgate S, Bisgaard H, Bjermer L, Haahtela T, Haughney J, Horne R, McIvor A, Palkonen S, Price DB, Thomas M, Valovirta E, Wahn U: The Brussels Declaration: the need for change in asthma management. Eur Respir J 2008, 32(6):1433-42.
• [5]Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST: Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004, 114(1):40-7.
• [6]Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsäter A, Bjermer L: Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008, 102(12):1681-93.
• [7]Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma. Respir Med 2008, 102(4):593-604.
• [8]Chrystyn H, Price D: Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J 2009, 18(4):243-9.
• [9]Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G, American College of Chest Physicians, American College of Asthma, Allergy, and Immunology: Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005, 127(1):335-71.
• [10]Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J: Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001, 5(26):1-149.
• [11]Schulte M, Osseiran K, Betz R, Wencker M, Brand P, Meyer T, Haidl P: Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv 2008, 21(4):321-8.
• [12]Molimard M, Le Gros V: Impact of patient-related factors on asthma control. J Asthma 2008, 45(2):109-13.
• [13]Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N: Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003, 16(3):249-54.
• [14]Bousquet J, Poli G, Acerbi D, Monno R, Ramael S, Nollevaux F: Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. Clin Pharmacokinet 2009, 48(6):347-58.
• [15]De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, Sommerer K, Meyer T, Mariotti F: Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD Patients. J Aerosol Med Pulm Drug Deliv 2010, 23(3):137-48.
• [16]Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J: Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103(1):41-9.
• [17]Fabbri LM, Nicolini G, Olivieri D, Papi A: Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother 2008, 9(3):479-90.
• [18]Usmani OS, Biddiscombe MF, Barnes PJ: Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005, 172(12):1497-504.
• [19]Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ: Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005, 18(4):379-85.
• [20]Partridge MR: Asthma: 1987-2007. What have we achieved and what are the persisting challenges? Prim Care Respir J 2007, 16(3):145-8.
• [21]Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: General considerations for lung function testing. Eur Respir J 2005, 26:153-161.
• [22]Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Inhaled Combination Asthma Treatment versus SYmbicort TBH (ICAT SY) Study Group: Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007, 29(4):682-9.
• [23]Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM, ICAT SE study group: Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007, 62(10):1182-8.
• [24]Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ: Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996, 154(5):1505-10.
• [25]Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, Hogg JC: Inflammation of small airways in asthma. J Allergy Clin Immunol 1997, 100(1):44-51.
• [26]Glover W, Chan HK, Eberl S, Daviskas E, Verschuer J: Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm 2008, 349(1-2):314-22.
• [27]Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O'Neill S, Ekström T: Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001, 18(2):262-8.
• [28]Foster JM, van Sonderen E, Lee AJ, Sanderman R, Dijkstra A, Postma DS, van der Molen T: A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Respir Res 2006, 7:131. BioMed Central Full Text
• [29]Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST: Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007, 119(6):1454-61.